Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Synergy Pharma Cmn (SGYP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,066,263
  • Shares Outstanding, K 224,950
  • Annual Sales, $ 0 K
  • Annual Income, $ -198,610 K
  • 36-Month Beta 1,016.65
  • Price/Sales 8,924.66
  • Price/Cash Flow N/A
  • Price/Book 9.86

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.34 +36.83%
on 05/31/17
4.84 -5.58%
on 06/26/17
+1.09 (+31.32%)
since 05/26/17
3-Month
3.34 +36.83%
on 05/31/17
4.86 -5.97%
on 03/28/17
-0.21 (-4.39%)
since 03/27/17
52-Week
3.34 +36.83%
on 05/31/17
7.15 -36.08%
on 01/31/17
+1.17 (+34.41%)
since 06/27/16

Most Recent Stories

More News
Today's Research Reports on Stocks to Watch: Synergy Pharmaceuticals and Bioscrip Inc.

NEW YORK, NY / ACCESSWIRE / June 5, 2017 / Synergy Pharmaceuticals had a pretty great day this past Friday after it was found out that Cantor Fitzgerald put a price target on the company that is roughly...

BIOS : 2.78 (+0.36%)
SGYP : 4.56 (-1.51%)
Allergan's Irritable Bowel Drug Viberzi Approved in Canada

Allergan plc (AGN) announced that Health Canada approved Viberzi (eluxadoline) for the treatment of adults suffering with irritable bowel syndrome with diarrhea (IBS-D)

IRWD : 18.69 (-1.53%)
AGN : 249.08 (+0.07%)
VRX : 16.98 (-0.59%)
SGYP : 4.56 (-1.51%)
Synergy Pharmaceuticals and Durect Corporation Both Sail Higher on Trader Optimism

NEW YORK, NY / ACCESSWIRE / May 15, 2017 / Both Synergy and Durect saw shares climb higher on Friday. Synergy's TRULANCE drug candidate has traders encouraged about the company's future while Durect Corporation's...

DRRX : 1.51 (+0.67%)
SGYP : 4.56 (-1.51%)
Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update

--Submitted Supplemental New Drug Application (sNDA) for TRULANCE for the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

SGYP : 4.56 (-1.51%)
Synergy Pharmaceuticals to Present Positive TRULANCE(TM) (Plecanatide) Phase 3 Data at Digestive Disease Week (DDW) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the company will present late-breaking data from Phase 3 studies evaluating TRULANCE(TM) (plecanatide) for the treatment of...

SGYP : 4.56 (-1.51%)
Synergy Presents New Insights at Digestive Disease Week (DDW) Examining Patient and Physician Perceptions and Experiences with Chronic Idiopathic Constipation (CIC)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced new insights that highlighted the frustrations many patients with chronic idiopathic constipation (CIC) feel with managing their...

SGYP : 4.56 (-1.51%)
Rasna Therapeutics Names Dr. Kunwar Shailubhai As New CEO

Rasna Therapeutics, Inc. (OTCQX:RASP), is pleased to announce the appointment of Dr. Kunwar Shailubhai as Chief Executive Officer.

RASP : 4.0000 (+2.56%)
SGYP : 4.56 (-1.51%)
Synergy Pharmaceuticals Announces Issuance of Three New Patents Expected to Extend TRULANCE(TM) (Plecanatide) Patent Protection Until 2032

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the United States Patent and Trademark Office (USPTO) has issued three new patents covering TRULANCE (plecanatide). The first...

SGYP : 4.56 (-1.51%)
Synergy Pharmaceuticals Launches the Poop Troop, the First Emoji Keyboard Designed to Support Dialogue Around Chronic Idiopathic Constipation (CIC)

Synergy Pharmaceuticals today announced the launch of the Poop Troop, a series of 14 animated emojis designed to encourage conversation and allow people to better express the physical...

SGYP : 4.56 (-1.51%)
Drug Makers Stocks Under Scanner -- Synergy Pharma, Novo Nordisk, Apricus Biosciences, and Sucampo Pharma

Stock-Callers.com has issued research reports on four Drug Manufacturers stocks, which are: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Apricus Biosciences Inc. (NASDAQ:...

SCMP : 10.70 (-0.47%)
NVO : 43.89 (-1.13%)
APRI : 1.03 (-3.74%)
SGYP : 4.56 (-1.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators are in flux.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant-...

See More

Support & Resistance

2nd Resistance Point 4.95
1st Resistance Point 4.79
Last Price 4.54
1st Support Level 4.52
2nd Support Level 4.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.